Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA Stock Report

Market Cap: US$8.2m

Processa Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:PCSA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Apr 26BuyUS$5,471George NgIndividual2,034US$2.69
30 Apr 26BuyUS$5,891Russell SkibstedIndividual2,190US$2.69
30 Apr 26BuyUS$5,342Sian BigoraIndividual1,986US$2.69
30 Apr 26BuyUS$4,702Wendy GuyIndividual1,748US$2.69
30 Apr 26BuyUS$4,065Patrick LinIndividual1,511US$2.69
30 Apr 26BuyUS$4,589David YoungIndividual1,706US$2.69
15 Apr 26BuyUS$5,892Russell SkibstedIndividual1,984US$2.97
15 Apr 26BuyUS$5,343Sian BigoraIndividual1,799US$2.97
15 Apr 26BuyUS$4,702Wendy GuyIndividual1,583US$2.97
15 Apr 26BuyUS$4,066Patrick LinIndividual1,369US$2.97
15 Apr 26BuyUS$4,589David YoungIndividual1,545US$2.97
15 Apr 26BuyUS$5,474George NgIndividual1,843US$2.97
31 Mar 26BuyUS$5,891Russell SkibstedIndividual2,324US$2.54
31 Mar 26BuyUS$5,752Khoso BaluchIndividual2,269US$2.54
31 Mar 26BuyUS$4,064Patrick LinIndividual1,603US$2.54
31 Mar 26BuyUS$5,341Sian BigoraIndividual2,107US$2.54
31 Mar 26BuyUS$4,700Wendy GuyIndividual1,854US$2.54
31 Mar 26BuyUS$5,253Geraldine PannuIndividual2,072US$2.54
31 Mar 26BuyUS$4,588David YoungIndividual1,810US$2.54
31 Mar 26BuyUS$2,000James NealIndividual789US$2.54
13 Feb 26BuyUS$199,999HX Entertainment LimitedCompany86,956US$2.30
05 Aug 25BuyUS$1,243,784HX Entertainment LimitedCompany218,687.24US$5.69
05 Aug 25BuyUS$1,243,784HX Entertainment LimitedCompany218,687.24US$5.69

Insider Trading Volume

Insider Buying: PCSA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PCSA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,7500.179%
Individual Insiders58,9332.22%
VC/PE Firms200,0007.52%
Institutions526,60719.8%
General Public1,869,74970.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 459.6%.

Top Shareholders

Top 25 shareholders own 29.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.5%
HX Entertainment Limited
305,644US$938.3k39.8%no data
7.52%
Heights Capital Management, Inc.
200,000US$614.0k0%0.2%
3.98%
Armistice Capital LLC
105,775US$324.7k0%0.01%
1.13%
Jane Street Group, LLC
30,190US$92.7k0%no data
0.89%
The Vanguard Group, Inc.
23,586US$72.4k105%no data
0.74%
Hudson River Trading LLC
19,691US$60.5k0%no data
0.58%
Geode Capital Management, LLC
15,323US$47.0k26.3%no data
0.54%
David Young
14,245US$43.7k50.8%no data
0.48%
UBS Asset Management AG
12,640US$38.8k0%no data
0.46%
Stonepine Capital Management LLC
12,323US$37.8k-70.1%0.01%
0.39%
George Ng
10,301US$31.6k140%no data
0.3%
Patrick Lin
7,976US$24.5k143%no data
0.28%
Sian Bigora
7,496US$23.0k457%no data
0.24%
Russell Skibsted
6,498US$19.9k0%no data
0.24%
Wendy Guy
6,441US$19.8k511%no data
0.087%
Khoso Baluch
2,325US$7.1k4,050%no data
0.085%
CorLyst, LLC
2,259US$6.9k0%no data
0.082%
Geraldine Pannu
2,188US$6.7k1,800%no data
0.052%
Tower Research Capital Europe Limited
1,390US$4.3k1,360%no data
0.047%
Richland Fund LLC
1,249US$3.8k0%no data
0.047%
Young Plaisance Revocable Trust
1,242US$3.8k0.24%no data
0.031%
James Neal
818US$2.5k2,720%no data
0.024%
Justin Yorke
645US$2.0k0%no data
0.00068%
Bank of America Corporation
18US$55.520%no data
0.00053%
Citigroup Inc.
14US$43.30%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 07:34
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Processa Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin Garner KalleyCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.
Nazibur RahmanMaxim Group